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2Abstract
Lactoferrin (LF) exerts a variety of biological effects, including the promotion of 
angiogenesis by increasing the expression of angiogenesis-related genes and reducing 
blood pressure via a nitric oxide-dependent mechanism. In the present study, we 
investigated the effects of LF on angiogenesis using C57BL/6J mice that received 
daily unilateral treatment with or without bovine milk-derived LF (bLF) following 
unilateral hindlimb surgery. The analysis of laser speckle blood flow showed that bLF 
treatment promoted blood flow recovery in response to ischemic hindlimb. The 
capillary density of ischemic adductor muscles, as well as the phosphorylation of Src, 
Akt, and endothelial nitric oxide synthase (eNOS) was also significantly higher in 
bLF-treated mice than in vehicle-treated mice. Furthermore, bLF increased the 
phosphorylation levels of Src, Akt, and eNOS in in vitro experiments using human 
aortic endothelial cells (HAECs). The action of bLF on eNOS phosphorylation was 
abolished by both LY294002, a phosphatidylinositol 3-kinase inhibitor, and PP2, a 
Src inhibitor. Similarly, bLF-induced acceleration of tube formation, cell proliferation, 
and cell migration in HAECs were inhibited by LY294002 or PP2. Thus, bLF 
promotes vascular endothelial cell function via an Src-Akt-eNOS dependent pathway, 
thereby contributing to revascularization in response to ischemia. 
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3Introduction
Lactoferrin (LF) is an 80-kD transferrin family, non-heme, iron-binding 
single-chain glycoprotein present in the secretory granules of neutrophils. LF is 
produced by mucosal epithelial cells and can be found in several biological exocrine 
fluids, including milk, and to a lesser extent, in bile, saliva, and tears (1). LF has 
various biological actions, including antibacterial and antiviral effects; antitumor 
activity; and functions involved in the regulation of the immune response, 
inflammation, and cellular growth, as well as in iron homeostasis (2). In addition, LF 
has been demonstrated to exert both angiogenic (3, 4) and antiangiogenic effects (5-7),
making its involvement in angiogenesis controversial. 
Angiogenesis plays a crucial role in the response to cardiovascular stress,
including myocardial infarction (8), cardiac ischemia/reperfusion injury (9), cardiac 
hypertrophy (10), and peripheral circulating insufficiency (11). The enhancement of 
angiogenesis is an important therapeutic strategy for patients with the above diseases, 
and many studies investigating angiogenic mechanisms have identified factors or 
drugs that can be used to treat ischemic organs. Of these, endothelial nitric oxide 
synthase (eNOS) has been shown to be a main target for angiogenesis in response to 
ischemic stress in both in vivo (11-13) and in vitro conditions (14).
LF directly exerts its action on endothelial cells (ECs) by binding to specific 
sites on ECs through classical LF receptors such as a low-density lipoprotein-receptor 
related protein (15). In rats, bovine LF (bLF) is capable of inducing hypotension in a 
nitric oxide (NO)-dependent manner through the regulation of aortic relaxation (16).
While this suggests that LF contributes to EC functions directly, the mechanism by 
which LF exerts effects on ECs has not yet been fully elucidated.
4In the present study, we investigated the mechanisms of bLF action on ECs
both in vitro and in vivo, and we showed that bLF promotes vascular endothelial 
function and angiogenesis in response to ischemia through a Src-Akt-eNOS-
dependent mechanism.
Methods
Materials
Bovine lactoferrin (bLF) was purchased from Calbiochem (San Diego, CA, USA). 
The following commercially available antibodies were used in this study: anti-
phospho-Akt (Ser473), anti-total Akt, anti-phospho-eNOS (Ser1177), anti-phospho-
Src (Tyr416) from Cell Signaling Technology (Beverly, MA, USA); anti-total eNOS 
and anti-Src from Santa Cruz Biotechnology (Santa Cruz, CA USA); anti-?-tubulin, 
as a loading control, from Calbiochem (San Diego, CA, USA); and anti-CD31 
(PECAM-1) from Becton, Dickinson and Company (BD; Tokyo, Japan). LY294002, 
a phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, and 4-amino-5-(4-
chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine (PP2), an Src inhibitor, 
were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Matrigel 
was obtained from BD Biosciences Japan (Tokyo, Japan). The CellTiter 96 AQueous 
nonradioactive cell proliferation assay kit ([3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) reagent) was 
purchased from Promega KK (Tokyo, Japan).
Culture of vascular endothelial cells
Human aortic endothelial cells (HAECs) were purchased from Takara Bio Inc. (Otsu, 
Japan) and cultured in EGM-2 (Lonza, Tokyo, Japan), according to the 
5manufacturer’s protocol. HAECs were passage from 5–8 times prior to use in each 
experiment. Cells were treated with bLF dissolved in sterilized water. In some 
experiments, cells were pretreated with LY294002 (2 μM), PP2 (1 μM), or vehicle 
alone for 30 min before bLF stimulation was initiated. 
Tube formation assay
Tube formation assays were performed on growth factor-reduced Matrigel (BD 
Biosciences, San Jose, CA, USA), as described previously (17). In brief, 1 × 104
HAECs were cultured per well of Matrigel-coated plates in the presence of each 
concentration of bLF or vehicle, with or without LY294002 (2 μM) or PP2 (1 μM). 
Cells were then incubated at 37°C for 18 h. The formation of tube-like structures in
the center field was observed using an inverted contrast microscope and captured with 
a CCD camera. Tube length was measured using the Image J 1.42 software.
Cell migration assay
Cell migration was evaluated using a modified Boyden chamber assay as described: 
2.0 × 104 ?????????????????????????????????????????????????????????????????????????????
and cultured for 6 h before cells that had migrated to the lower surface were fixed and 
stained with Giemsa stain solution. Five random microscopic fields per well were 
quantified.
Cell proliferation assay
6Cells were seeded in 96-well plates at 1 × 104 cells/well for 24 h; subsequently, bLf 
was added for 8 h and then proliferation was assessed 1 h after the addition of MTS 
reagent by measuring absorbance at 490 nm with a plate reader.
Assay for cell death induction by serum starvation
HAECs were cultured in 96-well plates at 1 × 104cells/well. Cells were incubated in 
EGM-2 as control or in serum- and growth factor-free EBM-2 with bLF or vehicle for 
48 h. Serum deprivation-induced cell death was evaluated by an MTS-based assay.
Murine model of ischemic hindlimbs
All experimental procedures were performed in accordance with the guidelines of the 
Animal Research Committee, University of Tokushima Graduate School. Eight-week-
old C57/BL6J mice were purchased from Nippon CLEA (Tokyo, Japan) and divided 
into 2 groups: a bLF (50 mg?kg-1?d-1)-treated group and a vehicle-treated group. Mice 
were injected intraperitoneally with either bLF or vehicle 3 d before the surgery to 
induce ischemia in the hindlimbs; the procedure used has been previously described 
(17). In brief, mice were anesthetized through intraperitoneal injection of 
pentobarbital (20 mg?kg-1) and subjected to unilateral hindlimb surgery. After ligation 
of the proximal and distal ends of the left femoral artery and vein, the entire artery 
and vein, with side branches, were resected.
Evaluation of peripheral blood flow
Hindlimb blood flow was measured before surgery and on postoperative days 0, 3, 7, 
14, and 28 using a laser speckle blood flow (LSBF) analyzing system (Omega Zone, 
7Omega Wave Co., Tokyo, Japan), as described previously (17).
Capillary density in adductor muscles
Analysis of capillary density in adductor muscle was performed by CD31 
immunohistochemistry (17). In brief, 28 d after surgery, adductor muscles were snap 
frozen in liquid nitrogen-cold isopentane containing OCT compound (Tissue-Tek, 
Sakura Finetek, Tokyo, Japan) and cryosectioned at 8 μm for immunohistochemistry 
and histological analyses. Capillary density was expressed as the number of CD31-
positive cells corrected for the number of muscle fibers.
Protein extraction and western blot analysis
The methods used to extract protein from ECs and adductor muscles, as well as the 
western blotting protocol, have been previously described in detail (17).
Immunoreactive bands were visualized using a chemiluminescence reagent (Forte 
Luminata Western HRP Substrates, Merck-Millipore, Billerica, MA), and membranes 
were exposed to Hyperfilm-ECL (GE Healthcare, Piscataway, NJ). Image J 1.42 
software was used for semiquantitative analysis of densitometry.
Blood pressure measurement
Blood pressure was measured by the tail-cuff method, as previously described (17).
Statistical analysis
Data have been expressed as mean ± standard error of mean (SEM) values. An 
unpaired 2-tailed Student’s t-test was used to evaluate the differences between 2 
8groups. For comparisons among more than 2 groups, statistical significance was 
assessed using a one-way analysis of variance (ANOVA), and the significance of each 
difference was determined by post hoc testing using Tukey-Kramer’s method. P
values of <0.05 were considered to indicate statistical significance.
Results
Effects of bLF on eNOS activation and cell function in HAECs
It is widely recognized that eNOS activation is important for angiogenesis in ECs (11).
First, we analyzed bLF action on eNOS phosphorylation in HAECs and found that 
bLF increased the phosphorylated levels of eNOS in a dose-dependent manner from 
0.1 to 1.0 μg/mL (Figure 1A). Our MTS-based assay demonstrated that treatment 
with 1.0 μg/mL bLF significantly promoted cell proliferation (Figure 1B). To assess 
the effect of bLF on cell death, HAECs were treated with bLF or vehicle and 
incubated for 48 h in serum-free medium. We observed that bLF also reduced serum 
deprivation-induced cell death, as assessed by an MTS-based assay (Figure 1C). 
Moreover, quantitative analysis of tube-like formation in HAECs showed that bLF 
significantly stimulated tube formation relative to control cells treated with vehicle 
alone (Figure 1D). Interestingly, we found that higher concentrations of bLF (10 and 
100 μg/mL) did not exert these proliferative effects, did not protect against serum 
starved-cell death, and did not promote tube formation in HAECs (Figure 1E-G). 
bLF increases eNOS phosphorylation through the Src-Akt pathway?
9We found that eNOS activation and Src and Akt phosphorylation increased 1 
h after bLF treatment (Figure 2). Because the PI3-kinase-Akt pathway is an important 
regulator of eNOS activation (18, 19) and Src is an upstream factor in PI3-kinase-
Akt-eNOS signaling (20), we tested whether the Src-PI3-kinase-Akt pathway was 
involved in bLF-stimulated eNOS phosphorylation by using LY294002, a PI3-kinase 
inhibitor, and PP2, an Src kinase inhibitor. Pretreatment with either LY294002 or PP2 
was found to markedly suppress bLF-stimulated eNOS activation (Figure 3A and E). 
Akt phosphorylation in response to bLF treatment was also diminished by PP2 
(Figure 3E). Taken together, these findings suggest that bLF activates eNOS 
phosphorylation via an Src-PI3-kinase-Akt dependent mechanism.
Effects of bLF on tube formation, proliferation, and migration in HAECs
The effects of bLF on EC activation were assessed using assays for tube formation, 
cell proliferation, and migration. Quantitative analysis of tube length demonstrated 
that bLF increased tube formation in a concentration-dependent manner (Figure 1D), 
while MTS and Boyden chamber assays showed that bLF also promoted HAEC 
proliferation and migration (Figures 1B and C). We assessed the involvement of PI3-
kinase, Akt, and Src in the pathway through which bLF activates cell tube formation, 
proliferation, and migration and found that bLF-activated EC functions were 
abolished by pretreatment with LY294002 or PP2 (Figure 3 A-D, Figure 3 E-H, 
respectively). Our results indicate that bLF promotes EC function through an Src-PI3-
kinase-Akt mediated pathway. 
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bLF treatment ameliorated angiogenesis in response to ischemia in vivo
To assess the effects of bLF on angiogenesis in vivo, we used a mouse model of 
unilateral hindlimb ischemia induced via surgery. As shown in Table 1, there were no 
differences in body weight, systolic blood pressure, or pulse beat 1 week after the 
operation between mice with or without bLF treatment; however, consecutive LSBF 
analyses showed that the blood flow recovery after hindlimb ischemia was better in 
mice treated with bLF than in mice treated with the vehicle. The rate of LSBF in bLF-
treated mice was also higher after 3 d and significantly increased at 7 d or later after 
ischemic hindlimb surgery, compared to that in control mice (Figure 4A). 
Capillary density in the ischemic adductor muscle of bLF-treated mice
CD31-positive cells were measured in histological sections of ischemic adductor 
muscles to evaluate the angiogenic response following induction of hindlimb 
ischemia. Capillary density was found to be higher in bLF-treated mice than in 
vehicle-treated mice on day 28 after surgery (Figure 4B). 
Action of bLF on eNOS, Akt, and Src phosphorylation in ischemic skeletal muscles
To identify the pathway through which bLF exerts its effects on angiogenesis, we 
assessed the phosphorylation levels of eNOS, Akt, and Src in ischemic skeletal 
muscle tissue. We found that eNOS phosphorylation, as well as Akt and Src 
phosphorylation, were significantly higher in the ischemic muscle tissues of mice 
treated with bLF than in mice treated with the vehicle on postoperative day 7 (Figure 
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4C). These results indicate that the effect of bLF on angiogenesis is exerted through 
Src-Akt-eNOS signaling, which is consistent with the findings for bLF action in vitro.
Discussion
In the present study, bLF was found to activate eNOS phosphorylation, tube 
formation, proliferation, and migration in ECs through an Src-Akt-dependent 
mechanism, leading to the promotion of angiogenesis. In an in vivo mouse model of 
hindlimb ischemia, bLF also augmented the phosphorylation of Src-Akt-eNOS and 
increased capillary number in ischemic adductor muscles, thereby contributing to the 
enhancement of blood flow recovery in response to ischemia.
LF is present in exocrine secretions from ECs such as milk and tears (1) and 
has a variety of biological functions, including antibacterial, antiviral, and 
anticarcinogenic activities, as well as functions in the regulation of the immune 
response, inflammation, cellular growth and differentiation, and iron homeostasis (2).
LF has also been implicated in various pathophysiological conditions. For instance, 
LF increases bone formation (21), and the oral administration of LF has been shown 
to ameliorate bone density in ovariectomized mice (22). The action that LF exerts on 
bone occurs through stimulation of the proliferation and differentiation of osteoblasts, 
as well as inhibition of the differentiation of osteoclasts, and can contribute to the 
treatment of osteoporosis. In studies on cancer, LF has been found to inhibit tumor 
growth and metastasis through iron chelation (23, 24) and cause growth arrest through 
the inhibition of G1 cyclin dependent-kinase (25). Recently, several studies have 
shown that LF is also involved in the promotion of angiogenesis. In 1 study, human 
LF was found to promote vascular endothelial growth factor (VEGF)-mediated 
angiogenesis in ECs through the upregulation of KDR/Flt-1 expression (4). Similarly, 
12
VEGF-mediated angiogenesis in ECs was enhanced by human apo-LF, but not human 
holo-LF (3). Finally, bLF has been shown to stimulate the expression of the 
angiogenic factors VEGF and fibroblast growth factor 2 via the extracellular regulated
kinase 1/2 pathway in osteoblast cells (26), as well as to exert effects on hypotension 
and vascular relaxation through an NO-mediated pathway (16). Under ischemic 
conditions, increased LF concentration has been shown to be a predictor for the risk 
of fetal ischemic heart disease in the case of diabetes (27), suggesting compensatory 
elevation of LF against ischemia. Additionally, oral LF administration reduces 
intestinal ischemia-reperfusion injury through antioxidative, anti-inflammatory, and 
antiapoptotic actions in rats (28). Thus, LF has the potential to promote angiogenesis 
and is effective for revascularization in response to ischemia.
In the present study, we also found that bLF enhanced ischemia-induced 
angiogenesis in vivo, in addition to increasing EC function in vitro through an eNOS-
dependent pathway. This bLF-induced eNOS activation was prevented by inhibitors 
of both PI3-kinase and Src, suggesting that bLF acts on eNOS in an Src-PI3-kinase-
Akt-dependent manner. Indeed, eNOS is well known to be an important factor of 
angiogenesis activated by Akt-dependent signaling (18, 19). Similarly, bLF induced 
eNOS phosphorylation and EC functions in this study. These effects were suppressed 
by LY294002, a PI3-kinase inhibitor, indicating that LF activates EC function in an 
Akt-dependent manner. We also found that bLF increased Src phosphorylation and 
that the Src kinase inhibitor PP2 suppressed bLF-induced eNOS phosphorylation and 
EC activation. Src kinase has also been shown to be an upstream regulator of PI3-
kinase-Akt-mediated eNOS activation by estrogen (20), a selective angiotensin II type 
1 receptor (29), and grape juice (30). Taken together, our results demonstrate that 
bLF-induced eNOS activation is mediated through Src-PI3-kinase-Akt signaling.
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In contrast to this study and other previous studies, several reports have shown 
LF to have an inhibitory effect on angiogenesis. For instance, the antitumor activity of 
bLF has been reported to be mediated by the inhibition of angiogenesis (6), and the 
oral administration of bLF has been found to inhibit VEGF-mediated angiogenesis in 
rats and ECs (5). Furthermore, bLF has been shown to suppress angiogenic activation 
in bovine aortic ECs (7). Thus, the effects of LF on angiogenesis remain controversial, 
although the results of the present study indicate that bLF activates endothelial 
function and promotes an ischemia induced-angiogenic response. While it is difficult 
to explain why our results are in opposition to those of previous studies, one plausible 
reason is that the doses of bLF used were different, ranging from 0.01 to 1 μg/mL in 
our study versus 10 to greater than 100 μg/mL in others. In support of this hypothesis, 
we found that a dose of 10 μg/mL bLF had no effect on cell proliferation or tube 
formation in HAECs. Further investigations are necessary to address different effects 
of bLF on angiogenesis.
Conclusion
In this study, we have shown that bLF promotes revascularization in response to 
ischemic stress through an Src-Akt-eNOS-dependent pathway. Our observations 
indicate that bLF may have potential as a candidate agent that could be used to induce 
angiogenesis.
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Figure legends
Figure 1. Effects of bLF treatment in HAECs. (A) Dose-dependent effects of bLF on 
eNOS phosphorylation. Protein was extracted 1 h after bLF treatment. Left panel: 
Representative blots of phospho-eNOS, total eNOS, and tubulin. Right panel:
Densitometric analysis of eNOS phosphorylation. Values are expressed in terms of 
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mean ± SEM. *P < 0.05, **P < 0.01, n = 6 in each group. (B) bLF action on 
endothelial cell proliferation. Cell proliferation was increased by bLF in a dose-
dependent manner. Values are expressed in terms of mean ± SEM. *P < 0.05, n = 6 in 
each group. (C) Effects of bLF on cell death induced by serum starvation. Cell death 
was inhibited by bLF in a dose-dependent manner. Values are expressed in terms of 
mean ± SEM. *P < 0.05, n = 8 in each group. (D) Effects of bLF on tube formation. 
Endothelial cell tube formation was induced by bLF in a concentration-dependent 
manner. *P < 0.05, n = 4 in each group.
(E) Dose effect of 1?100 μg/mL bLF on endothelial cell proliferation. Cell 
proliferation increased on treatment with 1 μg/mL bLF, but not at 10 or 100 μg/mL 
bLF. Values have been expressed in terms of mean ± SEM. *P < 0.05, n = 8 in each 
group. (F) Effect of 1?100 μg/mL bLF on cell death induced by serum starvation. Cell 
death was lower compared to that for the vehicle in the case of treatment with 1 
μg/mL bLF, but not in the case of 10 or 100 μg/mL bLF. Values are expressed in 
terms of mean ± SEM. *P < 0.05, n = 8 in each group. (G) Effect of 1?100 μg/mL 
bLF on tube formation. Endothelial cell tube formation was induced by treatment with 
1 μg/mL bLF, but not in the case of 10 or 100 μg/mL bLF. *P < 0.05, n = 4–5 in each 
group.
Figure 2. Time-dependent changes in eNOS, Akt, and Src phosphorylation in HAECs 
following bLF administration (1 μg/mL). Upper panel: Representative blots of 
phospho-eNOS, Akt, and Src, and total eNOS, Akt, Src, and tubulin. Lower panel:
Densitometric analysis of eNOS, Akt, and Src phosphorylation. The values have been 
expressed in terms of mean ± SEM. *P < 0.05, **P < 0.01, n = 8 in each group.
Figure 3. Analysis of PI3-kinase-Akt or Src pathway involvement in bLF-induced 
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endothelial cell activation. (A) The induction of eNOS phosphorylation by bLF was 
abolished by LY294002. Protein was extracted 1 h after bLF treatment. Left panel: 
Representative blots of phospho-eNOS and Akt, and total eNOS, Akt, and tubulin. 
Right panel: Densitometric analysis of eNOS and Akt phosphorylation. The values 
have been expressed in terms of mean ± SEM. *P < 0.05, **P < 0.01, n = 8 in each 
group. The increases in (B) tube formation, (C) cell proliferation, and (D) cell 
migration elicited in HAECs by bLF were inhibited by LY294002. The values have 
been expressed in terms of mean ± SEM. *P < 0.05, **P < 0.01, n = 6–8 in each 
group. (E) bLF-induced eNOS phosphorylation was abolished by PP2. Protein was 
extracted 1 h after bLF treatment. Left panel: Representative blots of phospho-eNOS 
and Akt, and total eNOS, Akt, and tubulin. Right panel: Densitometric analysis of 
eNOS and Akt phosphorylation. The values have been expressed in terms of mean ± 
SEM. *P < 0.05, **P < 0.01, n = 8 in each group. The increases in (F) tube formation, 
(G) cell proliferation, and (H) cell migration elicited in HAECs by bLF were inhibited 
by PP2. The values have been expressed in terms of mean ± SEM. *P < 0.05, **P <
0.01, n = 6–8 in each group.
Figure 4. bLF treatment promoted revascularization in response to hindlimb ischemia 
in mice. (A) Left panel: Quantitative evaluation of ischemic to non-ischemic laser 
speckle blood flow (LSBF) ratio in mice treated with vehicle or bLF before surgery 
and on postoperative days 0, 3, 7, 14, and 28. Right panel: Representative LSBF 
images for hindlimb ischemia in vehicle or bLF-treated mice. *P < 0.05, **P < 0.01 
vs. mice treated with vehicle, n = 8 in each group. (B) Immunohistochemical analysis 
of capillaries in skeletal muscles. Left panel: Representative immunohistological 
staining of anti-CD31 in ischemic hindlimbs from mice treated with the vehicle or 
bLF. Right panel: Quantification of capillary density in mice treated with the vehicle 
18
or bLF at 28 d after surgery. *P < 0.05 vs. mice treated with the vehicle, n = 5–6 in 
each group. (C) The levels of eNOS, Akt, and Src phosphorylation in the ischemic 
skeletal muscles of mice treated with the vehicle or bLF. Left panel: Representative 
blots of phospho- and total eNOS, Akt, and Src in the ischemic muscle tissue of mice 
treated with the vehicle or bLF at 7 d after surgery. Tubulin was used as a loading 
control. Right panel: Densitometric analysis of eNOS, Akt, and Src phosphorylation. 
The values have been expressed in terms of mean ± SEM. *P < 0.05, **P < 0.01, n =
6 in each group. ?
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Table.1 Body weight, Blood pressure and pulse rate at day 7 after ischemic hindlimb surgery
Post-surgery at day 7
vehicle bLF
BW (g) 22.0 ± 0.3 22.1 ± 0.3
Syst. BP (mmHg) 99 ± 3 100 ± 2
Dias. BP (mmHg) 68 ± 3 73 ± 4
Pulse rate (beats/min) 663 ± 20 680 ± 8
Values are mean ± SEM. n=6, respectively.
 
